Shavit Capital

MeMed Diagnostics Ltd. is a personalized diagnostics company founded in 2009 and headquartered in Tirat Carmel, Israel. The company specializes in developing innovative diagnostic solutions to enhance patient care and reduce healthcare costs by providing rapid and actionable insights for infectious diseases. Its flagship product, MeMed BV, is a test designed to distinguish between bacterial and viral infections, while the ImmunoDx platform utilizes proprietary biomarkers and algorithms to analyze patients' immune responses, helping physicians make informed antibiotic treatment decisions. MeMed's technologies aim to mitigate the misuse of antibiotics, which is a significant issue globally, leading to ineffective treatments and the emergence of resistant bacterial strains. By addressing the diagnostic gaps in infectious disease management, MeMed seeks to improve clinical outcomes and promote the responsible use of antibiotics.

Lightricks Ltd. is a mobile application developer based in Jerusalem, Israel, specializing in image processing and creativity tools that enhance visual content creation. Founded in 2013 by a team of entrepreneurs with expertise in computer graphics, image processing, machine learning, and artificial intelligence, the company offers a range of popular applications, including Facetune, Enlight, and Beatleap. These applications integrate advanced technologies such as computer vision and augmented reality, allowing users to easily edit and customize their photos and videos. Lightricks' portfolio includes tools for both personal and professional use, catering to individual users and small businesses alike, facilitating engagement and creativity through user-friendly mobile solutions.

KAHR Medical Ltd., established in 2005 and headquartered in Jerusalem, Israel, is a biopharmaceutical company specializing in immuno-oncology drug development. It focuses on creating fusion protein pharmaceuticals for treating cancer and autoimmune diseases. KAHR's proprietary technology involves developing 'third generation biological drugs,' which are unique fusion-protein molecules designed to activate immune responses by converting cancer cells' protective mechanisms into targets for the immune system. The company offers several candidates, including DSP105 and DSP106 for T-cell mediated tumor destruction, and DSP107 targeting CD47 tumors while delivering an immune costimulatory signal.

Veev Inc., founded in 2017 and headquartered in Minneapolis, Minnesota, is a building technology company that transforms the home construction and living experience. By utilizing its innovative home operating system, Veev provides clients with room-specific control over lighting, shading, and climate while enhancing security against intrusions and cyber threats. The company's construction approach incorporates modular systems featuring light gauge steel for framing, high-performance acrylic for surfaces, and advanced climate control technologies. Veev focuses on high-performance multifamily housing and accessory dwelling units, boasting a development pipeline of over 230 units, equating to 620,000 gross building square feet. Through comprehensive services that encompass design, permitting, modular construction, and a digital infrastructure, Veev empowers homeowners with enhanced control over their living environments.

Alpha Tau Medical Ltd. is an Israeli medical device company dedicated to the research, development, and commercialization of innovative cancer treatment solutions, specifically focusing on Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy). Established in 2016 and headquartered in Tel Aviv, the company leverages a technology developed at Tel Aviv University in 2003 that utilizes interstitial radioactive seeds to effectively target and treat solid tumors. Numerous preclinical trials have demonstrated the safety and efficacy of this approach, resulting in findings published in peer-reviewed journals. Currently, Alpha Tau Medical is conducting its first clinical trial, which has shown promising preliminary results, underscoring the potential of their technology in oncology therapeutics.

Syqe Medical Ltd. is a healthcare company based in Tel Aviv, Israel, founded in 2011. It specializes in transforming cannabis and other psychoactive botanicals into mainstream medical drugs. The company has developed the Syqe Inhaler Exo, a metered-dose inhaler designed for professional healthcare settings such as pain clinics, cancer centers, and intensive care units. This pocket-sized device allows for precise delivery of therapeutic molecules, ensuring predictable and consistent treatment. By utilizing automation and focusing on bioavailability, Syqe Medical aims to provide patients with effective symptom relief while minimizing psychoactive side effects, particularly for chronic neuropathic pain.

Alpha Tau Medical Ltd. is an Israeli medical device company dedicated to the research, development, and commercialization of innovative cancer treatment solutions, specifically focusing on Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy). Established in 2016 and headquartered in Tel Aviv, the company leverages a technology developed at Tel Aviv University in 2003 that utilizes interstitial radioactive seeds to effectively target and treat solid tumors. Numerous preclinical trials have demonstrated the safety and efficacy of this approach, resulting in findings published in peer-reviewed journals. Currently, Alpha Tau Medical is conducting its first clinical trial, which has shown promising preliminary results, underscoring the potential of their technology in oncology therapeutics.

Anchiano Therapeutics Ltd. is a preclinical biotechnology company focused on discovering, developing, and commercializing small molecule anti-cancer therapies. The company specializes in targeted cancer therapies designed to selectively destroy cancer cells while sparing healthy cells. Its primary development efforts are centered on the Pan-RAS Program, which identifies novel indene-based small molecules that inhibit activated RAS signaling, and the PDE10/ß-catenin program, aimed at selectively inhibiting PDE10 and suppressing Wnt/APC/ß-catenin signaling. Anchiano Therapeutics has a collaboration agreement with ADT Pharmaceuticals to further research these programs. Originally founded in 2004 as BioCancell Ltd., the company rebranded in July 2018 and is headquartered in Cambridge, Massachusetts. The company has developed drug candidates such as BC-819 and BC-821, with BC-819 having completed a Phase IIb clinical trial for bladder cancer.

Gamida Cell Ltd., established in 1998 and headquartered in Jerusalem, Israel, is a clinical-stage biopharmaceutical company focused on developing advanced cell therapies to treat blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, is an expanded hematopoietic stem cell therapy derived from umbilical cord blood, currently in Phase 3 studies for patients with high-risk hematologic malignancies and severe aplastic anemia. Additionally, Gamida Cell is developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 trials for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Both candidates leverage the company's proprietary expansion platform based on nicotinamide to enhance cell properties and therapeutic potential.

PolyPid Ltd. is a clinical-stage biopharmaceutical company headquartered in Petach Tikva, Israel, specializing in the development of advanced drug delivery systems based on its proprietary Polymer-Lipid Encapsulation MatriX (PLEX) technology. Founded in 2008, PolyPid's innovative platform allows for the entrapment of various active pharmaceutical ingredients (APIs) within a protective matrix, enabling controlled and prolonged release over extended periods, optimizing therapeutic regimens. The company’s product offerings include D-PLEX, an antibiotic reservoir designed to prevent surgical site infections, and several formulations aimed at addressing bone-related infections, such as BONYPID-1000 and BONYPID-500. PolyPid's technology supports localized drug administration across multiple therapeutic classes, highlighting its versatility in addressing diverse medical needs.

Mapi Pharma is a development-stage pharmaceutical company focused on creating high-barrier-to-entry generic drugs, including complex active pharmaceutical ingredients, formulations, and life cycle management products aimed at substantial markets. With a foundation in robust chemical and pharmaceutical research and development, Mapi leverages its understanding of global markets and regulatory requirements to establish lasting partnerships across various regions. The company is committed to delivering both generic and innovative intermediates and active pharmaceutical ingredients, as well as developing finished dosage forms for its internal programs or as generics of established brands. Headquartered in Israel, Mapi operates R&D facilities in Israel, China, and Germany, and is in the process of constructing an API manufacturing site in Neot Hovav. The company maintains a strong intellectual property position, actively filing patents for its APIs and formulations to protect its innovations.